<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940404</url>
  </required_header>
  <id_info>
    <org_study_id>ALOT-LC1</org_study_id>
    <nct_id>NCT03940404</nct_id>
  </id_info>
  <brief_title>Anlotinib Therapy in Patients With Advanced Lung Cancer.</brief_title>
  <official_title>Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in
      Patients with advanced Lung cancer in real world.

      Subjects of the study: advanced Lung cancer.

      Methods of the study:

      This is a real world, prospective, Non-Interventional, Follow-up registration study.

      Patients will get Anlotinib according to their condition and willingness. Anlotinib will give
      orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up
      after every cycle.

      End point:

      Primary end point: progression-free survival (PFS). Secondary end points: overall survival
      (OS), disease control rate (DCR), overall response rate (ORR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>1 year</time_frame>
    <description>overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>1 year</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>experiment</arm_group_label>
    <description>The patients whose treatment strategy containing anlotinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.</description>
    <arm_group_label>experiment</arm_group_label>
    <other_name>Other intervention depends on the patient's disease</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        advanced lung caner
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients â‰¥18 years of age, man or woman, who had to provide written informed consent
             prior to enrollment.

          2. Patients who had to have histologically and/or cytologically confirmed NSCLC that
             failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will
             obtain benefit from antiangiogenic therapy after investigator's assessment.

          3. Eastern Cooperative Oncology Group performance status of 0-2.

        Exclusion Criteria:

          1. Contraindication of anlotinib.

          2. Pregnant or lactating women.

          3. Other patients who can't enroll after investigator's assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenglin Ma</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Hangzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqin Chen</last_name>
    <phone>+8613735430109</phone>
    <email>chenlucy1437@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>300006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqin Chen</last_name>
      <phone>+8613735430109</phone>
      <email>chenlucy1437@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Xueqin Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shenglin Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 4, 2019</last_update_submitted>
  <last_update_submitted_qc>May 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

